The treatment of
Job syndrome includes a multidisciplinary approach aimed at managing recurrent skin and sinopulmonary infections as well as supportive care measures that improve the individual's quality of life. Acute infections can be managed with tailored antibiotics to the specific organism (e.g.,
fluconazole for
Candida spp.) and surgical drainage or debridement for
refractory infections. Antibiotic prophylaxis with
trimethoprim-sulfamethoxazole (TMP-SMX) can be useful in preventing further skin and sinopulmonary infections including
community-acquired Staphylococcus spp.
Other emerging immunomodulating therapies such as intravenous immunoglobulin (IVIG) and recombinant human
interferon-gamma have shown benefits in select individuals, although further evidence is needed to establish their long-term efficacy. Biologic therapies, such as
omalizumab (anti-
IgE monoclonal antibody), have been explored in small studies for controlling severe
eczema and reducing allergic inflammation. Experimental strategies targeting
STAT3 signaling or gene therapy are under investigation but remain at the preclinical stage.
Non-immune complications also require attention.
Osteoporosis can be treated with
bisphosphonates (e.g., alendronate, risedronate), which increase bone mineral density. Early referral to a dental specialist to extract primary retained teeth is helpful and helps avoid long-term dental complications like delayed
wound healing and jaw misalignment.
Supportive care measures include proper
skin care with emollients and avoidance of irritants, regular dental hygiene, and routine preventive
vaccinations (e.g., pneumococcal and
influenza vaccines) to reduce the risk of infection. Finally, genetic counseling can be offered to the individual a
nd their family members to better understand their condition and potential risks for future generations.